Approved HBV Drugs
Approved HBV Drugs
AASLD 2011: Long-term Tenofovir for HIV/HBV Coinfection
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Tenofovir showed long-term antiviral activity against hepatitis B virus (HBV) lasting 5 to 8 years, with minimal evidence of kidney toxicity, and HBsAg levels declined steadily over time, according to 2 posters presented this week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
Entecavir (Baraclude) Less Effective for Patients with Multidrug-Resistant Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 04 October 2011 00:00
- Written by Liz Highleyman
The nucleoside analog antiviral drug entecavir (Baraclude) was minimally effective against hepatitis B virus (HBV) that had already developed resistance to lamivudine (Epivir-HBV) and adefovir (Hepsera), researchers reported in the October 2011 Journal of Viral Hepatitis. Patient who achieved good early response, however, can do well if they stay on entecavir.
Early HBeAg Decrease Predicts Response to Entecavir (Baraclude) for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 August 2011 00:00
- Written by Liz Highleyman
Decreases in hepatitis B "e" antigen (HBeAg) during the first 6 months of treatment with entecavir (Baraclude) are a better indicator than hepatitis B virus (HBV) DNA levels of which patients will go on to achieve HBeAg seroconversion, according to a recent Chinese study.
Long-Term Efficacy of Entecavir for People with Hepatitis B
- Details
- Category: HBV Treatment
- Published on Wednesday, 17 August 2011 00:00
- Written by James Learned
Long-term entecavir (Baraclude) monotherapy leads to a virological response in a large majority of nucleoside/nucleotide analog-naive patients, even those who still have detectable HBV DNA at 48 weeks.
Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by James Learned
In a head-to-head comparison, entecavir (Baraclude) demonstrated superior virological efficacy compared to adefovir (Hepsera) in hepatitis B patients with decompensated liver disease.
Web Design and Development by